Jason Zemansky
Stock Analyst at B of A Securities
(4.86)
# 73
Out of 5,241 analysts
55
Total ratings
74.36%
Success rate
36.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Zemansky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $8 → $9 | $3.25 | +176.92% | 6 | Mar 30, 2026 | |
| INSM Insmed | Maintains: Buy | $211 → $213 | $109.14 | +95.16% | 12 | Mar 24, 2026 | |
| LGND Ligand Pharmaceuticals | Initiates: Buy | $244 | $213.21 | +14.44% | 1 | Mar 11, 2026 | |
| EIKN Eikon Therapeutics | Initiates: Buy | $34 | $13.25 | +156.60% | 1 | Mar 2, 2026 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $6 | $1.73 | +246.82% | 1 | Jan 21, 2026 | |
| KROS Keros Therapeutics | Maintains: Neutral | $18 → $19 | $10.50 | +80.95% | 3 | Nov 28, 2025 | |
| RCUS Arcus Biosciences | Maintains: Neutral | $17 → $26 | $23.78 | +9.34% | 6 | Nov 28, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Buy | $8 → $7 | $0.52 | +1,258.96% | 6 | Nov 18, 2025 | |
| CYTK Cytokinetics | Maintains: Neutral | $52 → $56 | $75.85 | -26.17% | 5 | Oct 2, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $29 → $31 | $42.59 | -27.21% | 4 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $29 | $9.22 | +214.53% | 2 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $31 | $20.23 | +53.24% | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $2.9 → $2.5 | $3.12 | -19.87% | 5 | Jun 20, 2024 |
Rocket Pharmaceuticals
Mar 30, 2026
Maintains: Buy
Price Target: $8 → $9
Current: $3.25
Upside: +176.92%
Insmed
Mar 24, 2026
Maintains: Buy
Price Target: $211 → $213
Current: $109.14
Upside: +95.16%
Ligand Pharmaceuticals
Mar 11, 2026
Initiates: Buy
Price Target: $244
Current: $213.21
Upside: +14.44%
Eikon Therapeutics
Mar 2, 2026
Initiates: Buy
Price Target: $34
Current: $13.25
Upside: +156.60%
Inhibikase Therapeutics
Jan 21, 2026
Initiates: Buy
Price Target: $6
Current: $1.73
Upside: +246.82%
Keros Therapeutics
Nov 28, 2025
Maintains: Neutral
Price Target: $18 → $19
Current: $10.50
Upside: +80.95%
Arcus Biosciences
Nov 28, 2025
Maintains: Neutral
Price Target: $17 → $26
Current: $23.78
Upside: +9.34%
Werewolf Therapeutics
Nov 18, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $0.52
Upside: +1,258.96%
Cytokinetics
Oct 2, 2025
Maintains: Neutral
Price Target: $52 → $56
Current: $75.85
Upside: -26.17%
Travere Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $29 → $31
Current: $42.59
Upside: -27.21%
Nov 22, 2024
Maintains: Buy
Price Target: $36 → $29
Current: $9.22
Upside: +214.53%
Aug 15, 2024
Maintains: Buy
Price Target: $30 → $31
Current: $20.23
Upside: +53.24%
Jun 20, 2024
Downgrades: Underperform
Price Target: $2.9 → $2.5
Current: $3.12
Upside: -19.87%